Your session is about to expire
← Back to Search
Semorinemab for Alzheimer's Disease
Study Summary
This trial will study whether semorinemab is effective and safe in treating patients with moderate Alzheimer's disease. The study will last for several months and will have patients in a placebo group and a treatment group.
- Alzheimer's Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 272 Patients • NCT03828747Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any open slots for potential participants in this research?
"Unfortunately, this trial is not currently taking on any new patients. It was initially posted in January 30th 2019 and last updated on September 1st, 2022. If you are looking for other studies to join, there are 546 concurrent medical trials searching for Alzheimer's disease (AD) participants and one study seeking enrolment of those with Semorinemab."
How hazardous is Semorinemab for individuals?
"There is a degree of safety data connected to semorinemab, which is why it was rated at 2 on our scale. However, as this trial remains in its Phase 2 stage, there isn't yet any evidence for efficacy."
How many healthcare facilities have implemented this trial?
"31 different medical institutions are presently conducting this trial, in locations such as Abington, Fort Myers and Wellington. To reduce the stress of travelling for participants, it is advisable to pick a clinic that is closest to you."
Have prior experiments explored the effects of Semorinemab?
"Currently, 1 clinical trial studying Semorinemab is being conducted. None of these trials are in the late Phase 3 stage. Toulouse and New jersey are two hubs for this research with a total of 51 sites around the world running studies on the potential treatment."
Has a clinical trial like this ever been undertaken previously?
"Since 2019, Genentech has sponsored a single trial for semorinemab across 32 cities and 4 countries. The first phase of the study was completed with 272 participants in that same year and 18,328 studies have concluded since then."
How many participants are enrolled in this research endeavor?
"Unfortunately, the aforementioned clinical trial has closed; with its first post dating to January 30th 2019 and most recent update on September 1st 2022. Currently, there are 546 trials accepting patients exhibiting Alzheimer's disease and a lone medical study utilizing Semorinemab that is enrolling volunteers."
What qualifications are necessary for participants to be included in this research endeavor?
"To qualify for this clinical trial, candidates must be diagnosed with Alzheimer's disease (AD) and aged between 50 and 85. The total number of participants required is 272 individuals."
Does this clinical trial accept participants of a minor age?
"This trial's entry requirements stipulate that those interested in joining must be between 50 and 85 years old."
Share this study with friends
Copy Link
Messenger